MLTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 15, 2025 deadline for a securities class action [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of MoonLake's Nanobodies compared to traditional monoclonal antibodies, leading to investor losses when the truth was revealed [5].